JP2014501712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501712A5 JP2014501712A5 JP2013538180A JP2013538180A JP2014501712A5 JP 2014501712 A5 JP2014501712 A5 JP 2014501712A5 JP 2013538180 A JP2013538180 A JP 2013538180A JP 2013538180 A JP2013538180 A JP 2013538180A JP 2014501712 A5 JP2014501712 A5 JP 2014501712A5
- Authority
- JP
- Japan
- Prior art keywords
- chem
- xaa
- lys
- histidine
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- -1 imidazopropionyl Chemical compound 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- WLNMZODBWIWRGN-SSDOTTSWSA-N (2R)-2-amino-2-formyl-3-(1H-imidazol-5-yl)propanoic acid Chemical compound C(=O)[C@](N)(CC1=CNC=N1)C(=O)O WLNMZODBWIWRGN-SSDOTTSWSA-N 0.000 claims 1
- OQQDUMSNEFAJOO-MRVPVSSYSA-N (2r)-2-amino-2-(1h-imidazol-5-ylmethyl)-3-oxobutanoic acid Chemical compound CC(=O)[C@@](N)(C(O)=O)CC1=CN=CN1 OQQDUMSNEFAJOO-MRVPVSSYSA-N 0.000 claims 1
- HSFOBLRKJTWQRO-ZCFIWIBFSA-N (2r)-2-amino-2-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@](O)(N)CC1=CN=CN1 HSFOBLRKJTWQRO-ZCFIWIBFSA-N 0.000 claims 1
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims 1
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 claims 1
- KQMBIBBJWXGSEI-ROLXFIACSA-N (2s)-2-amino-3-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CNC=N1 KQMBIBBJWXGSEI-ROLXFIACSA-N 0.000 claims 1
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 claims 1
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 claims 1
- UYEGXSNFZXWSDV-BYPYZUCNSA-N (2s)-3-(2-amino-1h-imidazol-5-yl)-2-azaniumylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CNC(N)=N1 UYEGXSNFZXWSDV-BYPYZUCNSA-N 0.000 claims 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 claims 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 claims 1
- IINRZEIPFQHEAP-UHFFFAOYSA-N 1-aminocycloheptane-1-carboxylic acid Chemical compound OC(=O)C1(N)CCCCCC1 IINRZEIPFQHEAP-UHFFFAOYSA-N 0.000 claims 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims 1
- PJSQECUPWDUIBT-UHFFFAOYSA-N 1-azaniumylcyclooctane-1-carboxylate Chemical compound OC(=O)C1(N)CCCCCCC1 PJSQECUPWDUIBT-UHFFFAOYSA-N 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
- 229930195721 D-histidine Natural products 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10190515.6 | 2010-11-09 | ||
| EP10190515 | 2010-11-09 | ||
| US41422110P | 2010-11-16 | 2010-11-16 | |
| US61/414,221 | 2010-11-16 | ||
| EP11169276.0 | 2011-06-09 | ||
| EP11169276 | 2011-06-09 | ||
| US201161497123P | 2011-06-15 | 2011-06-15 | |
| US61/497,123 | 2011-06-15 | ||
| PCT/EP2011/069743 WO2012062804A1 (en) | 2010-11-09 | 2011-11-09 | Double-acylated glp-1 derivatives with a linker |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016151098A Division JP2016188246A (ja) | 2010-11-09 | 2016-08-01 | リンカーを有する二重アシル化されたｇｌｐ−１誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014501712A JP2014501712A (ja) | 2014-01-23 |
| JP2014501712A5 true JP2014501712A5 (https=) | 2014-11-06 |
| JP6231386B2 JP6231386B2 (ja) | 2017-11-15 |
Family
ID=46050422
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538179A Active JP6039569B2 (ja) | 2010-11-09 | 2011-11-09 | 二重アシル化されたｇｌｐ−１誘導体 |
| JP2013538180A Active JP6231386B2 (ja) | 2010-11-09 | 2011-11-09 | リンカーを有する二重アシル化されたｇｌｐ−１誘導体 |
| JP2016151098A Withdrawn JP2016188246A (ja) | 2010-11-09 | 2016-08-01 | リンカーを有する二重アシル化されたｇｌｐ−１誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538179A Active JP6039569B2 (ja) | 2010-11-09 | 2011-11-09 | 二重アシル化されたｇｌｐ−１誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016151098A Withdrawn JP2016188246A (ja) | 2010-11-09 | 2016-08-01 | リンカーを有する二重アシル化されたｇｌｐ−１誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9006178B2 (https=) |
| EP (2) | EP2637699B1 (https=) |
| JP (3) | JP6039569B2 (https=) |
| CN (3) | CN103200966B (https=) |
| ES (2) | ES2913803T3 (https=) |
| WO (2) | WO2012062803A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750341A (en) | 1995-04-17 | 1998-05-12 | Lynx Therapeutics, Inc. | DNA sequencing by parallel oligonucleotide extensions |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| JP6039569B2 (ja) * | 2010-11-09 | 2016-12-07 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| JP6126097B2 (ja) | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体 |
| IN2014MN02304A (https=) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| EP2846823B1 (en) | 2012-05-08 | 2019-12-04 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| CN104411322B (zh) * | 2012-05-08 | 2017-05-24 | 诺和诺德股份有限公司 | 双酰化glp‑1衍生物 |
| IN2015DN00544A (https=) | 2012-07-23 | 2015-06-26 | Zealand Pharma As | |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| WO2014199397A2 (en) * | 2013-06-11 | 2014-12-18 | Mylan Laboratories Ltd | Process for the preparation of liraglutide |
| JP6475233B2 (ja) | 2013-06-20 | 2019-02-27 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| EP3016975B1 (en) | 2013-07-04 | 2019-01-16 | Novo Nordisk A/S | Derivatives of glp-1 like peptides, and uses thereof |
| EP3033112B1 (en) | 2013-08-15 | 2020-10-07 | Novo Nordisk A/S | Glp-1 derivatives, and uses thereof |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| PL3057984T3 (pl) | 2013-10-17 | 2018-12-31 | Zealand Pharma A/S | Acylowane analogi glukagonu |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| US10221315B2 (en) * | 2013-11-08 | 2019-03-05 | Ppg Industries Ohio, Inc. | Curable film-forming composition comprising catalyst associated with a carrier |
| ES2741507T3 (es) * | 2014-04-07 | 2020-02-11 | Novo Nordisk As | Compuestos de glp-1 acilados doblemente |
| KR102620911B1 (ko) | 2014-10-29 | 2024-01-05 | 질랜드 파마 에이/에스 | Gip 효능제 화합물 및 방법 |
| JP6730278B2 (ja) * | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| WO2016097108A1 (en) | 2014-12-17 | 2016-06-23 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| DK3283507T3 (da) | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
| AU2016270373A1 (en) | 2015-06-05 | 2018-01-04 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| US11358994B2 (en) | 2017-07-27 | 2022-06-14 | Saint Louis University | Fatty acid modified human epidermal growth factor |
| KR102665710B1 (ko) | 2017-08-24 | 2024-05-14 | 노보 노르디스크 에이/에스 | Glp-1 조성물 및 그 용도 |
| MX2020010505A (es) | 2018-04-05 | 2021-01-15 | Sun Pharmaceutical Ind Ltd | Analogos novedosos de glp-1. |
| CN113214381B (zh) * | 2018-04-19 | 2024-01-19 | 杭州先为达生物科技股份有限公司 | 酰化的glp-1衍生物 |
| WO2019200594A1 (zh) | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| JP7761567B2 (ja) | 2020-02-18 | 2025-10-28 | ノヴォ ノルディスク アー／エス | 医薬製剤 |
| CN114729060B (zh) | 2020-09-30 | 2022-11-25 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
| WO2022096636A1 (en) | 2020-11-06 | 2022-05-12 | Novo Nordisk A/S | Glp-1 prodrugs and uses hereof |
| CN116490212A (zh) * | 2020-11-06 | 2023-07-25 | 诺和诺德股份有限公司 | Glp-1前药及其用途 |
| WO2022244757A1 (ja) | 2021-05-18 | 2022-11-24 | 株式会社Ｌｔｔバイオファーマ | 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 |
| WO2022266927A1 (zh) * | 2021-06-24 | 2022-12-29 | 深圳翰宇药业股份有限公司 | 一种利拉鲁肽变构体及其制备方法、应用 |
| EP4323413A4 (en) | 2022-03-30 | 2025-10-15 | Beijing Ql Biopharmaceutical Co Ltd | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF |
| AR129270A1 (es) | 2022-05-10 | 2024-08-07 | Novo Nordisk As | Profármacos y usos de los mismos |
| JP2026502943A (ja) | 2022-12-30 | 2026-01-27 | アルギファルマ エーエス | 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法 |
| CN120676965A (zh) * | 2023-11-07 | 2025-09-19 | 深圳信立泰药业股份有限公司 | 多重受体共激动剂化合物及其制备方法与应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5336782A (en) | 1991-04-24 | 1994-08-09 | Kuraray Co., Ltd. | Long chain carboxylic acid imide ester |
| SE9102652D0 (sv) * | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| WO1999043706A1 (en) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| MY155270A (en) * | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
| BR122019021416A2 (https=) | 2003-09-19 | 2019-12-21 | ||
| EP2256130B1 (en) | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20110144010A1 (en) | 2007-06-01 | 2011-06-16 | Novo Nordisk A/S | Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| US20100317057A1 (en) * | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| ES2561208T3 (es) | 2008-09-12 | 2016-02-25 | Novo Nordisk A/S | Método de acilación de un péptido o una proteína |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| JP6039569B2 (ja) * | 2010-11-09 | 2016-12-07 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
-
2011
- 2011-11-09 JP JP2013538179A patent/JP6039569B2/ja active Active
- 2011-11-09 ES ES11779456T patent/ES2913803T3/es active Active
- 2011-11-09 EP EP11779674.8A patent/EP2637699B1/en active Active
- 2011-11-09 CN CN201180054105.XA patent/CN103200966B/zh active Active
- 2011-11-09 US US13/883,946 patent/US9006178B2/en active Active
- 2011-11-09 WO PCT/EP2011/069738 patent/WO2012062803A1/en not_active Ceased
- 2011-11-09 EP EP11779456.0A patent/EP2637698B1/en active Active
- 2011-11-09 CN CN201180054077.1A patent/CN103209711B/zh active Active
- 2011-11-09 ES ES11779674T patent/ES2683372T3/es active Active
- 2011-11-09 JP JP2013538180A patent/JP6231386B2/ja active Active
- 2011-11-09 US US13/882,947 patent/US9708383B2/en active Active
- 2011-11-09 WO PCT/EP2011/069743 patent/WO2012062804A1/en not_active Ceased
- 2011-11-09 CN CN201610182509.1A patent/CN105601729A/zh not_active Withdrawn
-
2015
- 2015-01-29 US US14/608,284 patent/US20150210745A1/en not_active Abandoned
-
2016
- 2016-08-01 JP JP2016151098A patent/JP2016188246A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501712A5 (https=) | ||
| JP2013543853A5 (https=) | ||
| JP2014529629A5 (https=) | ||
| RU2013148921A (ru) | Дважды ацилированные производные glp-1 | |
| JP2015517477A5 (https=) | ||
| JP2015517478A5 (https=) | ||
| JP2017514801A5 (https=) | ||
| JP2016523243A5 (https=) | ||
| JP2018506507A5 (https=) | ||
| JP2016529253A5 (https=) | ||
| JP2010538049A5 (https=) | ||
| JP2018505859A5 (https=) | ||
| JP2013517307A5 (https=) | ||
| KR102505628B1 (ko) | 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제 | |
| JP5969461B2 (ja) | Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用 | |
| US11167014B2 (en) | Solid glp-1 derivative compositions for oral administration | |
| RU2007134156A (ru) | Ацилированные glp-1 соединения | |
| JP2019513126A5 (https=) | ||
| JP2016526012A5 (https=) | ||
| WO2013004983A1 (en) | Novel compounds and their effects on feeding behaviour | |
| JP2014503526A5 (https=) | ||
| JP2007519642A5 (https=) | ||
| JP7432361B2 (ja) | ヒトインスリンまたはそのアナログのアシル化誘導体 | |
| JP2012506402A5 (https=) | ||
| JP2013514323A5 (https=) |